Author:
Schregel Christoph,John Hubert
Publisher
Springer Science and Business Media LLC
Reference7 articles.
1. System E‑ECI (2018) Estimates of cancer incidence and mortality in 2018, all cancer sites. https://ecis.jrc.ec.europa.eu. Zugegriffen: 24. Dez. 2021
2. Babjuk M, Burger M, Compérat E, Gontero P, Liedberg F, Masson-Lecomte A, Mostafid AH, Palou J, van Rhijn BWG, Rouprêt M, Shariat SF, Sylvester R, Capoun O, Cohen D, Dominguez Escrig JL, Seisen T, Soukup V (2021) European Association of Urology Guidelines: non-muscle-invasive bladder cancer. https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/. Zugegriffen: 24. Dez. 2021
3. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49(3):466–465. https://doi.org/10.1016/j.eururo.2005.12.031 (discussion 475–467)
4. Jahnen M, Kirchhoff FP, Gschwend JE, Straub M (2021) Transurethral resection of the urinary bladder: Status quo and outlook on new developments. Urologe A 60(11):1416–1423. https://doi.org/10.1007/s00120-021-01679-2
5. Gakis G (2021) Prophylaxis of recurrence in low-to-intermediate risk non-muscle invasive bladder cancer (NMIBC). Urologe A 60(11):1391–1399. https://doi.org/10.1007/s00120-021-01680-9